Ivermectin for preventing and treating COVID‐19
Maria Popp Miriam Stegemann Maria-Inti Metzendorf Susan Gould Peter Kranke Patrick Meybohm Nicole Skoetz Stephanie Weibel Authors' declarations of interest Version published: 28 July 2021 Version history
https://doi.org/10.1002/14651858.CD015017.pub2
Authors' conclusions
Based on the current very low‐ to low‐certainty evidence, we are uncertain about the efficacy and safety of ivermectin used to treat or prevent COVID‐19. The completed studies are small and few are considered high quality. Several studies are underway that may produce clearer answers in review updates. Overall, the reliable evidence available does not support the use of ivermectin for treatment or prevention of COVID‐19 outside of well‐designed randomized trials.
Ivermectin for preventing and treating COVID‐19 Maria Popp...
-
- There are more pages in this discussion • 160 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.08 |
Change
-0.015(1.38%) |
Mkt cap ! $1.235B | |||
| Open | High | Low | Value | Volume |
| $1.10 | $1.10 | $1.06 | $2.479M | 2.316M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 6089 | $1.08 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.08 | 61334 | 17 |
View Market Depth
| Last trade - 12.52pm 20/06/2024 (20 minute delay) ? |
| MSB (ASX) Chart |